Authors
Latest:
Dr. Vaena on Major Advances in Metastatic Prostate CancerDaniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.
Latest:
Dr. Daniel Von Hoff on Combination Treatments for Late Stage Pancreatic CancerDaniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.
Latest:
Dr. Bota on Marizomib in Patients with GliomaDaniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.
Latest:
Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung CancerDaniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.
Latest:
Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLLDanielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Standard of Care Continues to Shift in RCCToni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.
Latest:
Dr. Brander on Targeted Agents in CLLDanielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).
Latest:
Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell CarcinomaJanuary 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.
Latest:
Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AMLDanielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).
Latest:
Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell CarcinomaDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Dr. Rischin on the FDA Approval of Cemiplimab for CSCCDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.
Latest:
Dr. Dumoulin on NVALT 12 Data in NSCLCDaphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.
Latest:
Dr. Aisner on the Limitations of Molecular ProfilingDara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.
Latest:
Growing Pains: OCM Results Need Close LookDarcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.
Latest:
Darcy Burbage Discusses the Role of Nurses in Treating CIPNDarcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).
Latest:
Breast Cancer Expert Focuses on Decoding BiomarkersFor Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.
Latest:
Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal HemoglobinuriaDaria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.
Latest:
Institute Develops Fresh Bench-to-Bedside Model Through Community TiesIn more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.
Latest:
Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell LymphomaDarrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).
Latest:
Cleveland Clinic Study Finds Barriers to Precision Oncology in a Real-World TestAlthough precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.
Latest:
Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical TrialsDavendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
Latest:
Dr. Bond on Second Cancers Following CLL TreatmentDavid A. Bond, MD, assistant professor, The Ohio State University, discusses the high rates of second cancers in both treatment-naïve and pretreated patients with chronic lymphocytic leukemia who received BTK inhibitors.
Latest:
Dr Braun on Advancements in Biomarker Development in RCCDavid A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.
Latest:
Will Immunotherapy Become a Standard of Care for Glioblastoma?Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.
Latest:
Dr. Adelstein on Adjuvant Therapy for Oral CancerDavid Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.
